title: New insights into molecular mechanisms of sunitinib-associated side effects.
abstract: The introduction of targeted therapy represents a major advance in the treatment of tumor progression. Targeted agents are a novel therapeutic approach developed to disrupt different cellular signaling pathways. The tyrosine kinase inhibitor sunitinib specifically blocks multiple tyrosine kinase receptors that are involved in the progression of many tumors. Sunitinib is the current standard of care in first-line treatment of advanced renal cell carcinoma, and it is approved in imatinib-intolerant and imatinib-refractory gastrointestinal stromal tumors. However, it is increasingly evident that sunitinib may display collateral effects on other proteins beyond its main target receptors, eliciting undesirable and unexpected adverse events. A better understanding of the molecular mechanisms underlying these undesirable sunitinib-associated side effects will help physicians to maximize efficacy of sunitinib and minimize adverse events. Here, we focus on new insights into molecular mechanisms that may mediate sunitinib-associated adverse events.
authors.affiliation: Clinical Oncology Department and Biomedical Research Institute (INIBIC), A Coruña University Hospital, A Coruña, Spain.
authors.forename: Guadalupe
authors.initials: G
authors.lastname: Aparicio-Gallego
authors.forename: Moisés
authors.initials: M
authors.lastname: Blanco
authors.forename: Angélica
authors.initials: A
authors.lastname: Figueroa
authors.forename: Rosario
authors.initials: R
authors.lastname: García-Campelo
authors.forename: Manuel
authors.initials: M
authors.lastname: Valladares-Ayerbes
authors.forename: Enrique
authors.initials: E
authors.lastname: Grande-Pulido
authors.forename: Luis
authors.initials: L
authors.lastname: Antón-Aparicio
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D064420:Drug-Related Side Effects and Adverse Reactions / Q000235:genetics*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000235:genetics / Q000378:metabolism; D007037:Hypothyroidism / Q000139:chemically induced / Q000235:genetics / Q000378:metabolism; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008954:Models, Biological; D010859:Pigmentation Disorders / Q000139:chemically induced / Q000235:genetics / Q000378:metabolism; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects* / Q000235:genetics; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib